Skip to content
Netherlands Society of Gene and Cell Therapy

Netherlands Society of Gene and Cell Therapy

  • About
    • History
    • Mission
    • Board Members
    • Committees
    • Honorary Members
  • Education
    • Gene Therapy Basics
    • Cell Therapy Basics
    • Antisense Oligonucleotide Therapy Basics
    • Approved Therapies
  • Research
    • Academic Research on Gene and Cell Therapy in The Netherlands
    • Research vacancies
    • Research Image Gallery
    • Greiner Award
    • NVGCT Outstanding Achievement Award
    • Human Gene Therapy
    • Other Journals
    • Useful Links
    • Research News
  • Events
    • Webinars
    • Calendar
    • Annual Symposium
      • Program 2020
      • Patiënteninformatiedag Gentherapie
      • Registration 2020
      • Speed dating
      • Submit your abstract
    • Past events
      • Spring Symposium 2019
      • Spring Symposium 2018
  • Get Involved
    • Become a member
    • Become a sponsor
    • Contact
  • Patient Info (NL)
    • Dossier Gentherapie Stichting BWM
    • Patiënteninformatiedag Gentherapie
    • Veelgestelde vragen
  • Sign in
Posted on 13/01/202113/01/2021 by NVGCT

Gene therapy for a subtype of eye disease approved in the Netherlands

From 2021, patients suffering from RPE65-associated retinal disease will be able to be treated in three UMCs of the Netherlands.

https://www.radboudumc.nl/nieuws/2020/gentherapie-voor-zeldzame-oogziekte-vergoed

CategoriesUncategorized

Post navigation

Previous PostPrevious Scientists develop new gene therapy for eye disease | EurekAlert! Science News
Next PostNext In 2021 NVGCT would like to provide weekly updates about ATMPs in clinical development. Happy reading!

Aankomende activiteiten

There are no upcoming events.

View Calendar
Add
  • Add to Timely Calendar
  • Add to Google
  • Add to Outlook
  • Add to Apple Calendar
  • Add to other calendar
  • Export to XML
  • LinkedIn
Privacy Statement Proudly powered by WordPress